PRP Dosing and Formulation in Platelet Therapy

Unlocking the Potential of Regenerative Medicine: A Deep Dive into PRP Dosing and Formulation

Abstract

As a clinician and researcher dedicated to integrative and functional medicine, I am constantly exploring the most effective, evidence-based treatments for my patients. This post explores the science of Platelet-Rich Plasma (PRP) therapy, a cornerstone of regenerative medicine. We will journey through the complexities of what makes a PRP treatment successful, moving beyond a one-size-fits-all approach. I will explain the critical importance of dosing, cellular composition, and formulation. We will explore the latest research from leading experts, examining how factors such as platelet count, white blood cell presence, and patient age influence outcomes in conditions such as osteoarthritis and tendon injuries. This educational guide will illuminate why a nuanced, scientific understanding of PRP is essential for harnessing its full therapeutic power and how it integrates seamlessly with a holistic, patient-centered approach to healing that includes chiropractic care.

Hello, I’m Dr. Alex Jimenez. With my background as a Doctor of Chiropractic, Advanced Practice Registered Nurse, and certified functional medicine practitioner, my passion lies in integrating the best of modern medical science with a holistic understanding of the body’s innate healing capabilities. Today, I want to guide you through the exciting and evolving world of Platelet-Rich Plasma (PRP) therapy, sharing insights from leading researchers and my own clinical observations.

PRP is not just a simple injection; it’s a sophisticated biological therapy. To truly appreciate its potential, we must understand the intricate details of what we create and deliver to our patients. Let’s start with the basics.

What Exactly Are Platelets and Why Do We Concentrate Them?

It might be a distant memory from our early science education, but understanding the humble platelet is key to understanding PRP.

• Platelets are not complete cells but rather small, anucleated (lacking a nucleus) cell fragments that circulate in our blood.
• Despite their small size, they are powerhouses packed with hundreds of proteins, including crucial growth factors and cytokines.
• These bioactive proteins are the directors of the healing orchestra. When an injury occurs, platelets are among the first responders. They form a clot, but more importantly, they release signaling molecules that recruit other cells, regulate inflammation, and initiate repair of damaged tissue.

The core principle of PRP therapy is to harness this natural healing power. Through centrifugation, we take a patient’s blood sample and concentrate the platelets—along with their growth factor payload—into a small volume of plasma. The goal is to create a super-concentrated healing solution that we can inject precisely into an area of chronic injury or degeneration, effectively restarting a stalled healing process.

The FDA’s definition of PRP is quite broad, simply stating it’s a product with a platelet concentration above the baseline level in whole blood. This vagueness has led to a market filled with different commercial systems, each producing a different final product. This variability is a central theme we must address.

The “Rainbow of PRP”: Why Not All PRP Is Created Equal

A study by James and colleagues (2020) analyzed five commercial PRP systems and found significant variability in both the final platelet concentration and the number of white blood cells. In a compelling visual by another researcher, blood from the same patient was processed using four different systems, yielding four distinct PRP products—a veritable rainbow of colors and compositions.

This highlights a critical point: if we are to practice evidence-based medicine, we must know the specifics of the biologic product we are using. When colleagues or patients ask for the evidence behind PRP, it’s a complex conversation. Surprisingly, more patients are enrolled in high-quality studies of PRP for knee osteoarthritis (OA) than in those of hyaluronic acid injections (Bennell et al., 2021). The data is out there, but its interpretation is complicated by this product variability.

The Critical Concept of PRP Dosing

We don’t regulate PRP as a pharmaceutical drug, but we should consider it a biologic drug. Like any medication, there is a dose-response relationship. An insufficient dose will be subtherapeutic and fail to produce the desired effect, while an excessive dose could potentially be detrimental.

Dosing for Tendon and Soft Tissue Injuries

Emerging research is finally starting to define these therapeutic thresholds. For tendon injuries, studies suggest a “Goldilocks zone” for platelet concentration. Too few platelets, and you don’t stimulate enough tendon cell regeneration. Go above that optimal concentration, and you can actually see an inhibitory effect, with fewer new tenocyte cells being produced.

A pivotal meta-analysis by the Cleveland Clinic group reviewed numerous studies on PRP for soft-tissue applications (Warth et al., 2021). They carefully calculated the total platelet dose used in each study. The results were striking:

• Studies using a low dose (under approximately 3.5 billion total platelets) were predominantly negative, showing no significant benefit.
• Studies using a high dose (above the 3.5-billion-platelet threshold) were overwhelmingly positive.

This establishes a clear dose-dependent effect for soft tissue healing. If your system or protocol only yields 1.5 billion platelets, you may be consistently underdosing your patients and seeing poor results. To achieve a therapeutic effect, we need to aim for a dose in that higher range.

Dosing for Osteoarthritis (OA)

The area with the most robust dosing information is knee OA. A highly publicized study, the RESTORE trial, published in JAMA, concluded that PRP was no better than a placebo (Bennell et al., 2021). However, a deep dive into their methods reveals a critical flaw: they used a low-dose PRP system that delivered only about 1.6 billion platelets. Based on our understanding of the dose-response curve, this was a subtherapeutic dose, so the negative result was predictable. We learned a valuable lesson from this well-conducted study about what doesn’t work.

In stark contrast, we will now examine the study by van der Weegen and colleagues (2016), which is often discussed.

• They used a high dose of 10 billion platelets in a single injection for knee OA.
• They observed significant improvements not just in pain and function but also in cartilage health. MRI scans suggested a slowing of cartilage degradation, indicating a potential disease-modifying effect.

We are now able to plot a dose-response curve for knee OA, and the effective dose appears to be in the 5-10 billion platelet range. Knowing how to calculate this dose is paramount. Simply stating that a PRP is a “3x” or “5x” concentration is not enough. We must consider the starting platelet count, the volume of blood drawn, and the system’s efficiency to calculate the total number of platelets delivered to the joint. It’s the absolute dose, not the relative concentration, that matters.

Beyond Platelets: The Role of White and Red Blood Cells

While platelets are the stars of the show, they are not the only cells in the PRP production. The “buffy coat” layer, which is rich in platelets, also contains white blood cells (leukocytes).

• Neutrophils: These are pro-inflammatory cells. PRP rich in neutrophils (often called LR-PRP) can cause a more intense post-injection inflammatory reaction, leading to increased pain and swelling. In some cases, such as intra-articular injections in the shoulder, there is concern that these cells could damage the cartilage.
• Monocytes: These cells can differentiate into macrophages, which play a complex role in both orchestrating inflammation and resolving it to promote tissue remodeling.
• Red Blood Cells: We generally try to minimize red blood cells in the final product, as they can contribute to inflammation and oxidative stress within a joint.

The debate between Leukocyte-Rich (LR-PRP) and Leukocyte-Poor (LP-PRP) is ongoing. For knee OA, current evidence suggests there may not be a significant clinical difference in outcomes between the two, though LR-PRP tends to cause more post-injection pain. The choice of formulation may depend on the specific tissue being treated and the desired biological response. As practitioners, it is our responsibility to understand the cellular makeup of the PRP we prepare.

The Integrated Approach: Maximizing PRP Success

Producing a high-quality, appropriately dosed PRP product is only part of the equation for a successful outcome. At my clinics, we emphasize a comprehensive, integrative framework.

The Importance of Precision and Guidance

PRP works by forming a fibrin scaffold (a biological glue) at the site of injury, which holds the concentrated growth factors in place to orchestrate healing.

• If you are treating a partial tear in the Achilles tendon, the PRP must be injected precisely into that defect. If it’s injected into the surrounding healthy tissue, it cannot do its job.
• This is why ultrasound guidance is not a luxury; it is a necessity. It ensures that this potent biologic drug is delivered precisely where it is needed, maximizing its potential biological effect.

Chiropractic Care and Rehabilitation: The Essential Framework

The biological process initiated by PRP takes time. Patients will not feel better overnight. In fact, the initial inflammatory phase can last for several days. Healing and tissue remodeling occur over weeks and months. This is where a structured rehabilitation plan and integrative care become crucial.

• Biomechanical Integrity: As a chiropractor, my first priority is to ensure the patient’s body is moving correctly. If a patient with knee OA has poor hip stability, pelvic misalignment, or foot pronation, these biomechanical faults will continue to place abnormal stress on the knee joint. This stress can counteract the regenerative environment we are trying to create with PRP. Chiropractic adjustments, soft-tissue therapies, and functional movement screening are essential for resolving these underlying issues.
• Post-PRP Rehabilitation: A carefully designed physical therapy and rehabilitation protocol is mandatory. After a brief period of rest, we must introduce specific exercises to guide the new tissue as it forms. Proper loading of the healing tendon or joint helps the new collagen fibers align correctly, resulting in strong, functional, and resilient tissue. Without this mechanical signaling, the new tissue may heal in a disorganized, weaker state.

Patient Candidacy and Optimization

Finally, we must consider the patient’s overall health. Factors that impact healing potential include:

• Age: We know that older patients may have lower baseline platelet counts and function. For these individuals, we may need to draw a larger volume of blood to achieve the target therapeutic dose of 5-10 billion platelets.
• Nutrition and Lifestyle: A patient’s diet, hydration status, and inflammatory load all impact the quality of their blood and their healing capacity. As part of our functional medicine approach, we work with patients to optimize their health before the procedure, ensuring we start with the best possible biological material.

In my practice, we view PRP not as an isolated injection but as a powerful catalyst within a comprehensive healing program. By combining a scientifically formulated, accurately dosed, and precisely delivered PRP treatment with chiropractic care to restore biomechanical function and a tailored rehabilitation plan to guide tissue regeneration, we provide our patients with the greatest opportunity for a successful and lasting recovery.

The field of regenerative medicine is advancing rapidly. By staying committed to the evidence, understanding the nuances of the biologics we use, and treating the patient as a whole, we can truly unlock the body’s remarkable potential to heal.

References

Bennell, K. L., Paterson, K. L., Metcalf, B. R., Duong, V., Emsley, R., Burns, A. W., … & Hunter, D. J. (2021). Effect of intra-articular platelet-rich plasma vs placebo on pain and cartilage volume in knee osteoarthritis: The RESTORE randomized clinical trial. JAMA, 326(20), 2021–2030. https://doi.org/10.1001/jama.2021.19415

James, S. L., Ryan, E., Rourke, K., & Hogan, J. M. (2020). Variability of commercial platelet-rich plasma preparations: A point-of-care reference guide for clinical practice. Cureus, 12(12), e12041. https://doi.org/10.7759/cureus.12041

van der Weegen, W., van Drumpt, R., & de Leeuw, R. (2016). Pain and function after a single injection of a high-volume, leucocyte-poor platelet-rich plasma for knee osteoarthritis: A 12-month prospective study. International Journal of Orthopaedics, 3(5), 617-623. https://doi.org/10.17554/j.issn.2311-5106.2016.03.178

Warth, R. J., Dornan, G. J., James, E. W., & LaPrade, R. F. (2021). Platelet-rich plasma for soft tissue injuries: A new meta-analysis of dose and composition. Orthopaedic Journal of Sports Medicine, 9(2), 2325967120982559. https://doi.org/10.1177/2325967120982559